These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 14504378)

  • 1. Neuroprotection in PD--a role for dopamine agonists?
    Schapira AH
    Neurology; 2003 Sep; 61(6 Suppl 3):S34-42. PubMed ID: 14504378
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroprotection in Parkinson's disease.
    Montastruc JL; Rascol O; Senard JM
    Lancet; 1996 Jan; 347(8995):196. PubMed ID: 8544568
    [No Abstract]   [Full Text] [Related]  

  • 3. Attempts to obtain neuroprotection in Parkinson's disease.
    Olanow CW
    Neurology; 1997 Jul; 49(1 Suppl 1):S26-33. PubMed ID: 9222272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists.
    Kitamura Y; Taniguchi T; Shimohama S; Akaike A; Nomura Y
    Neurochem Res; 2003 Jul; 28(7):1035-40. PubMed ID: 12737528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine agonists and neuroprotection in Parkinson's disease.
    Olanow CW; Jenner P; Brooks D
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S167-74. PubMed ID: 9749590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical versus clinical neuroprotection.
    Grünblatt E; Schlösser R; Gerlach M; Riederer P
    Adv Neurol; 2003; 91():309-28. PubMed ID: 12442689
    [No Abstract]   [Full Text] [Related]  

  • 7. Neuroprotective mechanism of bromocriptine.
    Yamashita H; Kawakami H; Zhang YX; Tanaka K; Nakamura S
    Lancet; 1995 Nov; 346(8985):1305. PubMed ID: 7475755
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease.
    Schapira AH
    Neurology; 2009 Feb; 72(7 Suppl):S44-50. PubMed ID: 19221314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
    Olanow CW
    Neurology; 2009 Feb; 72(7 Suppl):S59-64. PubMed ID: 19221316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of early Parkinson's disease.
    Koller WC
    Neurology; 2002 Feb; 58(4 Suppl 1):S79-86. PubMed ID: 11909989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial agonist treatment of Parkinson disease: a critique.
    Albin RL; Frey KA
    Neurology; 2003 Feb; 60(3):390-4. PubMed ID: 12580185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trials of neuroprotection for Parkinson's disease.
    LeWitt PA
    Neurology; 2004 Oct; 63(7 Suppl 2):S23-31. PubMed ID: 15477583
    [No Abstract]   [Full Text] [Related]  

  • 13. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole.
    Albrecht S; Buerger E
    Curr Med Res Opin; 2009 Dec; 25(12):2977-87. PubMed ID: 19842998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When and how should treatment be started in Parkinson disease?
    Lang AE
    Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G
    Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydroergocryptine in the treatment of Parkinson's disease.
    Bonuccelli U; D'Antonio P; D'Avino C; Piccini P; Muratorio A
    J Neural Transm Suppl; 1995; 45():239-45. PubMed ID: 8748631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of dopamine agonists in the treatment of early Parkinson's disease.
    Olanow CW
    Neurology; 2002 Feb; 58(4 Suppl 1):S33-41. PubMed ID: 11909983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical importance of neuroprotection in Parkinson's disease.
    Riederer P; Gille G; Müller T; Przuntek H; Reichmann H; Riess O; Schwartz A; Schwarz J; Vogt T
    J Neurol; 2002 Oct; 249 Suppl 3():III/53-6. PubMed ID: 12522574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparative effects of medical therapies for Parkinson's disease.
    Horn S; Stern MB
    Neurology; 2004 Oct; 63(7 Suppl 2):S7-12. PubMed ID: 15477585
    [No Abstract]   [Full Text] [Related]  

  • 20. Future therapies for Parkinson's disease.
    Hauser RA; Lyons KE
    Neurol Clin; 2004 Oct; 22(3 Suppl):S149-66. PubMed ID: 15501363
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.